Ratings Autobio Diagnostics Co., Ltd.

Equities

603658

CNE100002GC4

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-14 pm EDT			5-day change	1st Jan Change
53.76 ^CNY	-0.59%		+0.02%	-5.70%

Apr. 02	Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 21, 2024.	CI
Apr. 01	Autobio Diagnostics Secures Registration Certificates for 11 Devices	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

The firm trades with high earnings multiples: 24.94 times its 2023 earnings per share.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AUTOBIO DIAGNOSTICS CO., LTD.	-5.70%	4.32B		C
BIOMÉRIEUX	+1.39%	13.22B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-15.79%	7.15B		B-
DIASORIN S.P.A.	-6.59%	4.97B		B
LANTHEUS HOLDINGS, INC.	-1.74%	4.13B		C
10X GENOMICS, INC.	-45.39%	3.92B		D+
ANDON HEALTH CO., LTD.	+7.49%	2.62B	-	-
VITROLIFE AB	-4.73%	2.38B		B-
MYRIAD GENETICS, INC.	-1.38%	1.72B		C
GUANGZHOU WONDFO BIOTECH CO.,LTD	-21.94%	1.53B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes